People · Operator
Named in public records as an officer, director or promoter · active 2017–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Frequency Therapeutics, Inc. | — | Biotechnology | Series C | $136.3M | $1.7B | 2017 |
Christopher R. Loose at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher R. Loose on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert S Langer | 1 | 14 |
| Timothy J. Barberich | 1 | 7 |
| Marc A. Cohen | 1 | 5 |
| Joel S. Marcus | 1 | 3 |
| David L. Lucchino | 1 | 2 |
| David Lucchino | 1 | 2 |
| Carl S. Lebel | 1 | 1 |
| Timothy R. Barberich | 1 | 1 |
| Joel R. Marcus | 1 | 1 |
| Marc R. Cohen | 1 | 1 |
| Marc R. Kozin | 1 | 1 |
| Robert R. Langer | 1 | 1 |
| Dana P. Hilt | 1 | 1 |
| Wendy S. Arnold | 1 | 1 |
| Richard S. Mitrano | 1 | 1 |
| Michael S. Huang | 1 | 1 |
| Carl P. LeBel | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.